Literature DB >> 20004021

A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition.

Jin Liu1, Congfeng Xu, Li-Chung Hsu, Yunping Luo, Rong Xiang, Tsung-Hsien Chuang.   

Abstract

Toll-like receptors play important roles in regulating immunity against microbial infections. Toll-like receptor 8 (TLR8) belongs to a subfamily comprising TLR7, TLR8 and TLR9. Human TLR8 mediates anti-viral immunity by recognizing ssRNA viruses, and triggers potent anti-viral and antitumor immune responses upon ligation by synthetic small molecular weight ligands. Interestingly, distinct from human TLR8, mouse TLR8 was not responsive to ligand stimulation in the absence of polyT-oligodeoxynucleotides (polyT-ODN). The molecular basis for this distinct ligand recognition is still unclear. In the present study, we compared the activation of TLR8 from different species including mouse, rat, human, bovine, porcine, horse, sheep, and cat by ligand ligations. Only the TLR8s from the rodent species (i.e., mouse and rat TLR8s) failed to respond to ligand stimulation in the absence of polyT-ODN. Multiple sequence alignment analysis suggested that these two rodent TLR8s lack a five-amino-acid motif that is conserved in the non-rodent species with varied sequence. This small motif is located in an undefined region of the hTLR8 ectodomain, immediately following LRR-14. Deletion mutation analysis suggested that this motif is essential for the species-specific ligand recognition of hTLR8, whereas it is not required for self-dimerization and intracellular localization of this receptor. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004021      PMCID: PMC2815190          DOI: 10.1016/j.molimm.2009.11.003

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  31 in total

1.  Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9.

Authors:  T H Chuang; R J Ulevitch
Journal:  Eur Cytokine Netw       Date:  2000-09       Impact factor: 2.737

2.  Pathogen recognition in the innate immune response.

Authors:  Himanshu Kumar; Taro Kawai; Shizuo Akira
Journal:  Biochem J       Date:  2009-04-28       Impact factor: 3.857

3.  Dendritic cell inhibitory and activating immunoreceptors (DCIR and DCAR) in duck: Genomic organization and expression.

Authors:  Xiaoxin Guo; William G Branton; Debra A Moon; Jianguo Xia; Megan R W Macdonald; Katharine E Magor
Journal:  Mol Immunol       Date:  2008-07-26       Impact factor: 4.407

Review 4.  Structures of the toll-like receptor family and its ligand complexes.

Authors:  Mi Sun Jin; Jie-Oh Lee
Journal:  Immunity       Date:  2008-08-15       Impact factor: 31.745

5.  Characterization of equine and other vertebrate TLR3, TLR7, and TLR8 genes.

Authors:  Natalia M Astakhova; Andrey A Perelygin; Andrey A Zharkikh; Teri L Lear; Stephen J Coleman; James N MacLeod; Margo A Brinton
Journal:  Immunogenetics       Date:  2009-07-01       Impact factor: 2.846

6.  Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells.

Authors:  T Chuang; R J Ulevitch
Journal:  Biochim Biophys Acta       Date:  2001-03-19

7.  Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.

Authors:  Hiroaki Hemmi; Tsuneyasu Kaisho; Osamu Takeuchi; Shintaro Sato; Hideki Sanjo; Katsuaki Hoshino; Takao Horiuchi; Hideyuki Tomizawa; Kiyoshi Takeda; Shizuo Akira
Journal:  Nat Immunol       Date:  2002-01-22       Impact factor: 25.606

8.  Characterization of bovine Toll-like receptor 8: ligand specificity, signaling essential sites and dimerization.

Authors:  Jianzhong Zhu; Robert Brownlie; Qiang Liu; Lorne A Babiuk; Andrew Potter; George K Mutwiri
Journal:  Mol Immunol       Date:  2008-11-08       Impact factor: 4.407

Review 9.  Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins.

Authors:  Susan Carpenter; Luke A J O'Neill
Journal:  Biochem J       Date:  2009-07-29       Impact factor: 3.857

Review 10.  Variation matters: TLR structure and species-specific pathogen recognition.

Authors:  Dirk Werling; Oliver C Jann; Victoria Offord; Elizabeth J Glass; Tracey J Coffey
Journal:  Trends Immunol       Date:  2009-02-09       Impact factor: 16.687

View more
  45 in total

Review 1.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.

Authors:  Christopher B Rodell; Sean P Arlauckas; Michael F Cuccarese; Christopher S Garris; Ran Li; Maaz S Ahmed; Rainer H Kohler; Mikael J Pittet; Ralph Weissleder
Journal:  Nat Biomed Eng       Date:  2018-05-21       Impact factor: 25.671

3.  Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.

Authors:  Alyson J Smith; Yufeng Li; Hélène G Bazin; Julien R St-Jean; Daniel Larocque; Jay T Evans; Jory R Baldridge
Journal:  Vaccine       Date:  2016-07-09       Impact factor: 3.641

4.  Distinct evolution of toll-like receptor signaling pathway genes in cetaceans.

Authors:  Ran Tian; Inge Seim; Zepeng Zhang; Ying Yang; Wenhua Ren; Shixia Xu; Guang Yang
Journal:  Genes Genomics       Date:  2019-09-18       Impact factor: 1.839

5.  TLR8 Couples SOCS-1 and Restrains TLR7-Mediated Antiviral Immunity, Exacerbating West Nile Virus Infection in Mice.

Authors:  Amber M Paul; Dhiraj Acharya; Linda Le; Penghua Wang; Dobrivoje S Stokic; A Arturo Leis; Lena Alexopoulou; Terrence Town; Richard A Flavell; Erol Fikrig; Fengwei Bai
Journal:  J Immunol       Date:  2016-10-21       Impact factor: 5.422

6.  Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.

Authors:  Bradley J Monk; Andrea Facciabene; William E Brady; Carol A Aghajanian; Paula M Fracasso; Joan L Walker; Heather A Lankes; Kristi L Manjarrez; Gwenn-Äel H Danet-Desnoyers; Katherine M Bell-McGuinn; Carolyn K McCourt; Alexander Malykhin; Robert M Hershberg; George Coukos
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

7.  Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).

Authors:  Christopher P Mussari; Dharmpal S Dodd; Ratna Kumar Sreekantha; Laxman Pasunoori; Honghe Wan; Shana L Posy; David Critton; Stefan Ruepp; Murali Subramanian; Andrew Watson; Paul Davies; Gary L Schieven; Luisa M Salter-Cid; Ratika Srivastava; Debarati Mazumder Tagore; Shailesh Dudhgaonkar; Michael A Poss; Percy H Carter; Alaric J Dyckman
Journal:  ACS Med Chem Lett       Date:  2020-07-29       Impact factor: 4.345

Review 8.  Female predisposition to TLR7-driven autoimmunity: gene dosage and the escape from X chromosome inactivation.

Authors:  Mélanie Souyris; José E Mejía; Julie Chaumeil; Jean-Charles Guéry
Journal:  Semin Immunopathol       Date:  2018-10-01       Impact factor: 9.623

9.  A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.

Authors:  Gabriela Maria Wiedemann; Severin Johannes Jacobi; Michael Chaloupka; Angelina Krächan; Svetlana Hamm; Stefan Strobl; Roland Baumgartner; Simon Rothenfusser; Peter Duewell; Stefan Endres; Sebastian Kobold
Journal:  Oncoimmunology       Date:  2016-05-31       Impact factor: 8.110

10.  Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.

Authors:  Arta M Monjazeb; Michael S Kent; Steven K Grossenbacher; Christine Mall; Anthony E Zamora; Annie Mirsoian; Mingyi Chen; Amir Kol; Stephen L Shiao; Abhinav Reddy; Julian R Perks; William T N Culp; Ellen E Sparger; Robert J Canter; Gail D Sckisel; William J Murphy
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.